Medication Management and Culture of Safety

Not Applicable

Completed

• Conditions: Cardiovascular Disease
• Interventions: Behavioral: EHR prompt and patient prompt; Behavioral: academic detailing; Behavioral: Electronic Health Record (EHR) prompt

• Registration Number: NCT01247454
• Lead Sponsor: University of Colorado, Denver

Brief Summary

There will be no significant decrease in the use of low dose acetylsalicylic acid (ASA) therapy for primary prevention across the three intervention arms from baseline to completion of the project.

There will be no significant differences in the percentage of patients with diabetes mellitus greater than 44 years of age on low dose ASA therapy for primary prevention across the three arms of the study using repeated measures from baseline to completion of the project.

Detailed Description

We will assess the current use of aspirin therapy for primary and secondary cardiovascular disease prevention in six general internal medicine and family medicine clinics within the University of Colorado Hospital system using electronic health record data.

We will develop messages concerning the appropriate use of aspirin for cardiovascular disease prevention for academic detailing to clinicians, a point of care (EHR) decision support aid for clinicians, and a short information sheet (generated by a CDS) for patients.

We will test the effectiveness of interventions to improve the evidence-based use of aspirin for primary and secondary prevention of cardiovascular disease using a randomized trial in the six University of Colorado Hospital primary care practices studied. The three intervention arms will include:

1.academic detailing and cessation of the primary prevention reminder within the point of care clinical decision support system (EHR/CDS) only 2. academic detailing with an EHR/CDS message asking clinicians to consider stopping aspirin therapy for primary prevention embedded in the point of care clinical decision support system 3. academic detailing with the EHR/CDS point of care message for clinicians in the second paragraph above, and a short information sheet to be given to patients prior to a visit to ask them to check with their provider concerning their use of aspirin for primary prevention

-

Study Timeline

• Study Start: 2009-07
• Primary Completion: 2009-12
• Study Completion: 2010-09
• Study First Submitted: 2010-11-19
• Study First Submitted QC: 2010-11-23
• Study First Posted: 2010-11-24
• Status Verified: 2019-04
• Last Update Submitted: 2019-04-15
• Last Update Posted: 2019-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 7000

Inclusion Criteria

• All patient on low-dose aspirin without an appropriate diagnosis of coronary artery disease or thrombotic stroke/transient ischemic attack (TIA) within the six practices.

Read More

Exclusion Criteria

• Persons not on aspirin therapy or persons on aspirin therapy for reasons other than prevention of cardiovascular disease (i.e., pain relief) will not be included in the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EHR prompt and patient prompt	EHR prompt and patient prompt	The final arm will receive this combined intervention plus the academic detailing
academic detailing	academic detailing	All arms will receive this intervention
Electronic Health Record (EHR) prompt	Electronic Health Record (EHR) prompt	One intervention arm will receive the EHR prompt along with the academic detailing

Primary Outcome Measures

Name	Time	Method
Using a baseline cohort design is there any difference in the number of patients on ASA based on EHR medication lists for apparent primary prevention among the three groups after 24 months.	12 months later

Trial Locations

Locations (1)

University Hospital Clinics; 🇺🇸 Denver, Colorado, United States